Now On Demand | Hosted by Fierce PharmaWATCH NOW
In this session, Sapient discusses application of its next-generation mass spectrometry approaches for large-scale biomarker discovery across diverse human diseases, enabling measure of tens of thousands of small molecule biomarkers across tens of thousands of individuals. See how integration of these biomarker studies with human genetics data is an approach for aligning the right patient, with their specific disease, and the optimal therapy to enhance drug efficacy and limit adverse events.
Learn why circulating small molecules biomarkers are uniquely suited as non-invasive means to interrogate human biology and drug response, and how next-generation mass spectrometry allows for rapid biomarker identification and cross validation across large, diverse populations. You’ll also see real-world case reports in which Sapient has leveraged its platform to identify specific biomarkers of biological processes, disease progression (even years prior to onset), and drug responsiveness.
Now On Demand | Hosted by Fierce Pharma WATCH NOW In this session, Sapient discusses application of its next-generation mass spectrometry approaches for large-scale biomarker discovery across diverse human diseases, enabling measure of tens of thousands of small… Read More
What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Disease Prediction, Diagnostics and Therapies
Now On Demand | Hosted by AAPS WATCH NOW While next-generation sequencing has been instrumental in advancing genomics-based precision medicine, the full potential of personalized therapy has yet to be realized at scale. DNA biomarkers help identify genetic… Read More
Mapping the Missing Link: Bridging the Gap Between Human Genetics and Disease Biology Through Small Molecule Biomarker Discovery
Now On Demand | Hosted by AAPS WATCH NOW Genome-wide association studies (GWAS) have been transformative in elucidating the genetic landscape of human disease, defining hundreds of common and rare genetic variants that contribute to the development… Read More
Now On Demand | Hosted by AAPS WATCH NOW A key aspect of the drug discovery pipeline is evaluation of in vivo target engagement and subsequent biological response. While measures of target engagement are often optimized in cellular… Read More
Now On Demand | Hosted by AAPS WATCH NOW Diseases are singularly defined but often represent varied groupings of contributing factors and pathways that ultimately produce a shared pathology. Heterogeneous molecular pathogenesis creates heterogeneity in treatment responsiveness, which… Read More
Now On Demand | Hosted by AAPS WATCH NOW Circulating biomarkers are a critical component of the drug discovery process, enabling understanding of complex disease processes, personalization of therapy, evaluation of target engagement, clinical trial optimization, and pharmacometric modeling. Read More